The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

The chief executive of generic-drug maker Sandoz SDZ0.35%increase; up pointing triangle Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, though ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

WASHINGTON, April 29 (Reuters) - The U.S. Supreme Court on Wednesday heard a patent dispute over a generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular drug Vascepa that could ...

The era of cheap, officially approved semaglutide is finally here—in Canada, that is. The country has just become the first in North America and the first G7 nation to license a generic version of the ...

Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Persistent shortages (216 active at end‑2025) impose major operational costs (~$900M labor/year) and hit oncology, anesthesia, and emergency care, forcing substitutions and compounding with safety and ...

Merck’s guidance for the year—anticipating sales between 20 billion euros and 21 billion euros, or -1% to 2% growth— “assumes no U.S. sales of Mavenclad from March 2026 amid generic competition.” ...